Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

Jagsonpal Pharmaceuticals Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Assets

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash & Equivalents	1,153	100.42	110.28	127.6	110.53	225.26
Short-Term Investments	-	957.64	1,175	1,352	1,036	245.31
Cash & Short-Term Investments	1,153	1,058	1,285	1,479	1,146	470.57
Cash Growth	-27.62%	-17.69%	-13.11%	29.06%	143.59%	-24.34%
Accounts Receivable	374.96	171.91	131.76	109.51	208.72	155.77
Receivables	374.96	171.91	131.76	109.51	208.72	155.77
Inventory	265.89	146.43	152	149.97	206.76	297.42
Prepaid Expenses	-	16.63	16.62	16.02	10.68	10.62
Other Current Assets	61.39	37.86	26.11	212.95	73.17	156.43
Total Current Assets	1,855	1,431	1,612	1,968	1,646	1,091
Property, Plant & Equipment	73.74	73.5	88.37	93.02	242.78	225.73
Long-Term Investments	244.71	845.32	168.62	47	33.84	290.55
Goodwill	183.12	96.93	96.93	-	-	0.3
Other Intangible Assets	793.38	682.67	759.24	-	-	-
Other Long-Term Assets	28.74	37.46	57.5	62.97	27.25	34.86
Total Assets	3,183	3,167	2,783	2,171	1,949	1,642

Liabilities

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Accounts Payable	268.3	115.81	97.34	75.96	165.8	185.5
Accrued Expenses	20.65	115.69	112.13	81.71	88.86	79.86
Short-Term Debt	8.96	-	-	-	-	-
Current Portion of Leases	18.02	15.76	16.07	13.84	7.54	-
Current Income Taxes Payable	17.33	5.57	-	-	0.19	2.33
Current Unearned Revenue	-	9.35	9.1	12.94	6.12	-
Other Current Liabilities	208.46	20.8	24.4	6.83	7.2	2.03
Total Current Liabilities	541.72	282.98	259.04	191.28	275.71	269.72
Long-Term Leases	65.18	65.89	76.32	75.57	52.47	-
Long-Term Deferred Tax Liabilities	84.36	44.41	30.7	20.73	21.63	32.38
Other Long-Term Liabilities	48.55	11.77	17.04	9.18	10.75	12.56
Total Liabilities	739.81	405.05	383.1	296.76	360.56	314.66

Shareholders' Equity

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Common Stock	132.12	133.93	132.8	132.19	130.99	130.99
Additional Paid-In Capital	-	248.64	140.56	111.2	6	6
Retained Earnings	-	2,174	1,906	1,460	1,363	1,112
Comprehensive Income & Other	2,274	204.78	219.65	170.7	88.52	78.87
Shareholders' Equity	2,443	2,762	2,400	1,874	1,589	1,328
Total Liabilities & Equity	3,183	3,167	2,783	2,171	1,949	1,642

Additional Metrics

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Total Debt	92.16	81.65	92.39	89.41	60.01	-
Net Cash (Debt)	1,060	976.41	1,193	1,390	1,086	470.57
Net Cash Growth	-29.49%	-18.16%	-14.16%	27.96%	130.84%	-15.07%
Net Cash Per Share	15.64	14.31	17.72	20.96	16.59	7.18
Filing Date Shares Outstanding	66.06	66.96	66.4	66.09	65.5	65.5
Total Common Shares Outstanding	66.06	66.96	66.4	66.09	65.5	65.5
Working Capital	1,313	1,148	1,353	1,777	1,370	821.09
Book Value Per Share	36.42	41.24	36.14	28.35	24.26	20.27
Tangible Book Value	1,430	1,982	1,543	1,874	1,589	1,327
Tangible Book Value Per Share	21.64	29.60	23.24	28.35	24.26	20.27
Land	-	-	-	-	87.59	87.59
Buildings	-	-	-	-	163.8	163.8
Machinery	-	16.25	14.77	20.38	18.02	329.61

Data Source: S&P Global Market Intelligence Last updated: Oct 28, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 9, 2026

Data Sources Report a data error